Methods & measurement development
Here you can explore our current active projects and publications within methods & measurement development.
Current Projects
-
Consensus well-being measures
Trials of psychedelic therapies report improvements that symptom scales capture only partly, and no two trials measure the remainder the same way. CEP is making the case for well-being as a co-primary endpoint in npj Mental Health Research in 2026. The next stage is the Delphi consensus process that paper calls for: building and validating a single instrument the field can agree on. The stakes are economic as well as scientific, since payers cannot assign value to an outcome that every trial defines differently.
-
New Mexico psilocybin program
New Mexico is building a state psilocybin program, and the questions that will decide who it reaches are delivery questions: what group-based care looks like in practice, who is qualified to staff it, and what it costs per person served. With the Psychedelic Mental Health Access Alliance, CEP is working on those questions alongside the community engagement process that is shaping the program’s design, rather than modeling the program from the outside after the fact. The population the state program is built to serve is largely a Medicaid population, so what the work produces travels to other states.
Publications
-
Well-being as a primary endpoint in clinical trials: a call for consensus.
Marseille E, Kettner H, Sgambati TJ, Kahn JG, Bertozzi S, Lucas W, Carhart-Harris R, Keltner D, Raison C. Well-being as a primary endpoint in clinical trials: a call for consensus. npj Mental Health Research. 2026;5:39.
Psychiatric trials judge success mainly by symptom reduction, while patients describe recovery in terms of meaning, vitality, and functioning. This paper makes the case for adopting well-being as a co-primary endpoint, developed through a Delphi consensus process into a validated instrument, with safeguards against treatments that raise well-being while leaving the underlying condition untreated.
-
Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico
Leeman L, Armstrong M, Menashi D, Nayo-Washington H, Marseille E, Herrera J, Romero C, Page-Reeves J. Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico. Frontiers in Public Health. 2026;14. June 16, 2026.
Describes how community engagement was used to build the foundation for implementation research on group psilocybin-assisted therapy in New Mexico, and what that process changed about how the work was designed.
-
The economics of psychedelic-assisted therapies: a research agenda
Marseille E, Bertozzi S, Kahn JG. The economics of psychedelic-assisted therapies: a research agenda. Frontiers in Psychiatry. 2022;13:1025726. doi:10.3389/fpsyt.2022.1025726
Sets out the economic questions the field has to answer before coverage and scale-up become possible, and the order in which they need answering. It is the framing paper behind much of CEP’s subsequent work.